tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

FRLN

Acquisition of Freeline by Syncona becomes effective
The FlyAcquisition of Freeline by Syncona becomes effective
7M ago
FRLN
Acquisition of Freeline by Syncona Becomes Effective
PremiumPress Releases
Acquisition of Freeline by Syncona Becomes Effective
7M ago
FRLN
Freeline Shareholders Approve Acquisition by Syncona
PremiumPress Releases
Freeline Shareholders Approve Acquisition by Syncona
7M ago
FRLN
Freeline shareholders approve acquisition by Syncona
PremiumThe Fly
Freeline shareholders approve acquisition by Syncona
7M ago
FRLN
Freeline downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Freeline downgraded to Neutral from Buy at H.C. Wainwright
10M ago
FRLN
Syncona to Acquire Freeline Therapeutics
PremiumPress ReleasesSyncona to Acquire Freeline Therapeutics
10M ago
FRLN
Freeline enters agreement to be acquired by Syncona
Premium
The Fly
Freeline enters agreement to be acquired by Syncona
10M ago
FRLN
Freeline Therapeutics Holdings PLC (ADR) trading resumes
Premium
The Fly
Freeline Therapeutics Holdings PLC (ADR) trading resumes
11M ago
FRLN
Freeline Therapeutics Holdings PLC (ADR) trading halted, volatility trading pause
PremiumThe Fly
Freeline Therapeutics Holdings PLC (ADR) trading halted, volatility trading pause
11M ago
FRLN
Freeline announces new data from GALILEO-1 trial of FLT201
PremiumThe Fly
Freeline announces new data from GALILEO-1 trial of FLT201
11M ago
FRLN
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
PremiumPress Releases
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
11M ago
FRLN
Freeline downgraded to Neutral from Outperform at Wedbush
PremiumThe Fly
Freeline downgraded to Neutral from Outperform at Wedbush
11M ago
FRLN
Freeline to present new clinical data for FLT201 at ESGCT Congress
PremiumThe FlyFreeline to present new clinical data for FLT201 at ESGCT Congress
11M ago
FRLN
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
Premium
Press Releases
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
11M ago
FRLN
Stifel keeps Hold on Freeline despite positive Phase 1/2 GALILEO-1 update
Premium
The Fly
Stifel keeps Hold on Freeline despite positive Phase 1/2 GALILEO-1 update
12M ago
FRLN
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
PremiumPress Releases
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
12M ago
FRLN
Freeline reports initial data from first cohort of Phase 1/2 GALILEO-1 trial
PremiumThe Fly
Freeline reports initial data from first cohort of Phase 1/2 GALILEO-1 trial
12M ago
FRLN
Freeline price target raised to $4 from $3 at Stifel
PremiumThe Fly
Freeline price target raised to $4 from $3 at Stifel
1y ago
FRLN
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
PremiumPress Releases
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
1y ago
FRLN
Freeline expects initial clinical data from GALILEO-1 trial in Q3
PremiumThe FlyFreeline expects initial clinical data from GALILEO-1 trial in Q3
1y ago
FRLN
Freeline expects cash to fund operations into 2Q24
Premium
The Fly
Freeline expects cash to fund operations into 2Q24
1y ago
FRLN
Freeline reports 1H EPS (23c) vs. (95c) last year
Premium
The Fly
Freeline reports 1H EPS (23c) vs. (95c) last year
1y ago
FRLN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >